Benha Journal of Applied Sciences (BJAS) **print: ISSN 2356–9751**
Vol. (9) Issue (8) (2024), (73- 79) **online: ISSN 2356–976x**
http://bjas.bu.edu.eg

Transarterial Chemoembolization for Inoperable Early-Stage Hepatocellular Carcinoma in Patients with Child-Pugh Grade A

Mohamed A.Elserwi, Talal A.Amer and Mohamed M.Faheem
Diagnostic and Interventional Radiology Dept., Faculty of Medicine, Benha University
E-mail : bfm7md89@gmail.com

Abstract
Background: Gastrointestinal cancer As the main killer of cirrhotic patients, HCC is a major worldwide health problem, accounting for more than 5% of all malignancies. The goal of this review was to talk about how TACE responds to tumours in people who have HCC that is Child Pugh Grade A. Results: Patients with Child-Pugh Grade A early-stage hepatocellular carcinoma who are unable to undergo surgery may benefit greatly from TACE, as shown by the study's 60% complete response rate. Importantly, the research found that a good prognosis after TACE is strongly predicted by a lower tumour size, the lack of an expanded belly, and ultrasonography homogeneity. In order to optimise patient selection and improve clinical results for HCC patients, it is crucial to consider tumour features and clinical presentation when predicting TACE outcomes.

Keywords: Chemoembolization of the A-stage liver tumour that cannot be surgically removed; Child-Pugh grade A.

1. Introduction

Patient classification and treatment allocation are determined by tumour stage, liver function tests, and performance status for hepatocellular carcinoma (HCC), the most prevalent primary liver cancer. HCC is the sixth major cause of cancer and the third leading cause of cancer-induced death (1).

Medical, surgical, and non-surgical approaches are all available for the treatment of HCC (2).

Efficacious palliative and, to a lesser degree, curative treatment is required because, despite the tremendous progress in the treatment of (HCC) and the availability of various curative options, a large percentage of patients aren't candidates for these treatments due to advanced tumour stage or poor general patient condition (3).

Patients diagnosed with HCC, regardless of size or number of nodules, are first treated with transarterial chemoembolization (TACE) according to the Barcelona Clinic Liver Cancer staging system (3).

Two methods exist for transdermal acupuncture catheterisation: drug-eluting bead-assisted TACE (DEB-TACE) and conventional TACE (cTACE). Lipiodol is an oily radio-opaque substance that serves as both a chemotherapeutic carrier and an embolic material in cTACE. The procedure begins with the administration of a cytotoxic drug such doxorubicin, epirubicin, mitomycin, or cisplatin. Collage, degradable starch microspheres (DSM), and gelatine sponge are among the other embolic agents that are often used. DEB-TACE makes use of chemotherapeutic medicines packaged with non-resorbable embolic microspheres, which may release the agent continuously (4).

Patients' tumour load, liver function, and overall performance status are all factors in determining the best course of therapy for hepatocellular carcinoma (HCC) (5).

The survival advantage of (TACE) has just been shown, and it is now conventional therapy for certain patients (3).

Patients with (HCC) Child Pugh Grade A were the focus of this review paper, which aimed to address the tumour response to transarterial chemoembolization (TACE).

The Liver: A General Overview

Located in the belly's upper right quadrant, the liver is a massive organ. Detoxification, protein synthesis, bile generation, and nutrient storage are just a few of the important roles played by this multi-organ auxiliary organ of the digestive system. At almost 1.5 kilogrammes, it is the heaviest gland found in a human body. It aids in the upkeep of fundamental homeostatic systems and functions in tandem with several other organs (6).

Except for the exposed region where the liver rubs against the diaphragm, the visceral peritoneum entirely encases the liver (6).

The liver's blood supply determines the division of its four morphological lobes into even smaller parts. The left lobe is smaller and more flattened than the right lobe, which is the biggest of the four. The inferior vena cava and gallbladder fossae divide these two lobes. Between the inferior vena cava and the ligamentum venosum fissure is where you'll find the caudate lobe, and between the gallbladder and the ligamentum teres hepatis fissure is where you'll find the quadrate lobe (7).

The liver's two primary surfaces are the visceral surface and the diaphragmatic surface. Visceral peritoneum covers the latter, with the exception of the porta hepatis and the gallbladder's bed. Several anatomical structures are directly associated to this surface, including the duodenum, gallbladder, hepatic flexure of the colon, transverse colon, right kidney, and suprarenal gland. With the exception of the exposed region, the visceral peritoneum covers the diaphragmatic surface, which rests against the inferior side of the diaphragm (7).

The Liver in a Normal CT Scenario:

Computed tomography (CT) scans of the liver provide high-quality anatomical images in axial sections; however, these images may be reshaped to produce sagittal or coronal views of the organ. All of the lobes and fissures, in addition to the biliary channels and intrahepatic vasculatures, are clearly visible (8).

There are four scissures that split the liver into eight sections. The transverse scissura is located at the level of the right and left major portal trunk in the axial plane, whereas the longitudinal scissurae are three in number and aligned with the three hepatic veins. Using axial CT imaging, lines that go straight through the three hepatic veins from the inferior venae cava match up with the longitudinal scissurae, which are the segment borders (8).

The plane of the middle hepatic vein divides the liver into two lobes, one on the right side and one on the left. This line follows Cantlie's axis, which begins at the inferior vena cava (IVC) and continues to the gallbladder fossa on the left. Along the course of the right hepatic vein, the right lobe is segmented into two halves, one located anteriorly and the other posteriorly. Obliquely linking the left hepatic vein and the falciform ligament, the left lobe is separated into a medial and lateral sectors or parts. As seen in Figure 4, the liver is bifurcated at the level of the major portal vein (MPV), dividing it into upper and lower portions. the ninth

Prior to any interventional procedures or surgical procedures, it is crucial to assess the liver's vascular and biliary architecture for any anatomical variations. When measuring functional liver reserve, choosing a therapy, and predicting prognosis, hepatic volume evaluation might be useful. the ninth

Segmentation is based on the fact that each segment has its own biliary drainage and lymphatic drainage in addition to its own dual vascular input. One way to think of each segment is as a wedge, with the tip pointing towards the hepatic hilum. This is where the portal triad, which consists of one segmental branch, enters. A hepatic vein drains two neighbouring segments, and each segment contains several draining hepatic veins, resulting in venous outflow along the boundary of each segment. the ninth

Gastrointestinal cancer

The vast majority of primary liver tumours, over 90% to be exact, are hepatocellular carcinomas (HCCs). Roughly 85 percent of cirrhotic individuals develop hepatocellular cancer. As of recently, HCC ranked as the world's sixth most prevalent cancer killer. It kills more males than any other cancer, second only to lung cancer (10).

Second only to pancreatic cancer in terms of five-year survival rate, HCC is at 18%. (10) that is prevalent in patients with long-term liver conditions, including cirrhosis brought on by hepatitis B or C antibodies.

Things that might put you at risk:

Anything that raises the probability of cancer in a given individual is considered a risk factor. While several variables might increase a person's chance of developing cancer, few actually cause the disease on their own. Cancer may develop in some individuals despite having many risk factors, but it can also occur in others who have no recognised risk factors. In order to make better lifestyle and health care decisions, it may be helpful to be aware of the following risk factors for liver cancer and to discuss them with your doctor. 10. Cirrhosis and nonalcoholic fatty liver disease (NAFLD) are the primary dangers.

The Histology of Hepatocellular carcinoma

Regardless of the underlying aetiology, hepatocellular carcinomas are thought to originate from cycles of necrosis and regeneration. A second method by which infection with HBV and HCV predisposes to hepatocellular carcinoma is that their genomes include genetic information that may cause cells to accumulate mutations or alter growth regulation. (11)

There are distinct physical and phenotypic characteristics of HCC. Patient care for HCC is anticipated to be affected by our growing understanding of the disease and its pathophysiology (11)

Physical Characteristics:

There are different types of single HCC, including: vaguely nodular, expanding nodular, multinodular confluent, nodular with peri-nodular extension, infiltrative, and non-nodular with a circumference of less than 50% or more than 50%. These types of tumours are characterised by a lack of clear borders between the tumor's interior and exterior. (11)

Results are better for a single nodular HCC than for many nodules, peri-nodules, or infiltrative development patterns. Multiple distinct tumours may be present in as many as 30% of instances with HCC. Here, it's important to note the total number of lesions and provide detailed descriptions of each one. A little nodule that is near (< 2 cm) to the primary tumour is called a satellite nodule. (12)

Molecular and microscopic Characteristics:

Liver HCC develops in a multistep sequence that begins with pre-neoplastic lesions (e.g., dysplastic foci, LGDN, and HGDN) and progresses to early neoplastic lesions (e.g., early HCC, pHCC, and small and progressed HCC) that are defined by progressive accumulation of morphological and molecular abnormalities (13).

Molecular investigations on the growing number of clonal molecular changes corroborate this categorisation as well (12).

Incidental findings in chronic liver disease (CLD) include the presence of microscopic lesions called dysplastic foci, which are less than 1 mm in size. The dysplasia in these foci is comparable to that in dysplastic nodules, with characteristics such as massive cell change, minor cell change, or a localised iron free region (13).

Hepatocytes often multinucleate, cytoplasm is plentiful, and cellular size is increased, all of which are hallmarks of big cell transformation. Even with massive cell division, the nuclear-cytoplasmic ratio remains constant (14).

Hyperchromasia, modest nuclear pleomorphism, cytoplasmic basophilia, increased nuclear-cytoplasmic ratio, and reduced cell volume are the hallmarks of small cell transformation (14).

There is a significant frequency of HCC and immunohistochemistry evidence of proliferative activity in iron-free foci seen in individuals with substantial hepatic iron excess (14).

While cirrhosis is the most common cause of dysplastic nodules in the liver, CLD without cirrhosis is also sometimes seen. These may be one or many lesions, and their diameters range from 5 to 15 mm (15).

(LGDN): compared to the surrounding cirrhotic liver, this nodular lesion has a uniform cell population, a little increase in cell density, a characteristic trabecular structure, and no architectural atypia (15).

(HGDNs): Hepatocyte proliferation with abnormal cytological and/or architectural characteristics characterises HGDNs, but does not adequately indicate HCC. A increased cellular density and, more often than not, minor cell changes are hallmarks of HGDN (16)

Pathology of HCC under the microscope:

β-catenin, encoded by CTNNB1 and involved in cholestatic HCC, is an important intracellular transducer of the WNT signalling system that controls liver function and zonation. The stabilisation and subsequent nuclear accumulation of β-catenin, which increases cell proliferation and survival, is caused by mutations in CTNNB1. Micro-trabecular and pseudo-glandular growth patterns, intra-tumoral cholestasis, absence of immune infiltration, glutamine synthetase (GS), and nuclear β-catenin expression at the phenotypic level are characteristics of HCCs mutant in CTNNB1. sixteen (16)

Regardless of the accompanying cytological characteristics, macro-trabecular-massive HCC (MTM-HCC) is characterised by the existence of an architectural pattern that makes up a significant amount (>50%) of the lesion. This pattern is characterised by trabeculae that are >6 cells thick. Aggressive clinicopathological features, such as vascular (microand/or macro) invasion and many satellite nodules, are linked with these. The majority of patients with MTM-HCC also have high levels of alpha-fetoprotein serum and are infected with HBV. (16). A number of features are characteristic of MTM-HCCs, including angiogenesis activation, TP53 mutations and/or FGF19 amplification, and the overexpression of VEGFA and angiopoietin 2. (16) A new research confirmed that MTM-HCC is marked by increased expression of angiogenesis-related genes and found ESM1 to be a particular biomarker of MTM-HCC endothelial cells (EC) at the immune-histochemical level (16).

Neoplastic cells and thick fibrous stroma are hallmarks of the scirrhous subtype of hepatocellular carcinoma (HCC). It is common for tumour cells to display markers that are linked to cancer stem cells or progenitors, such as CK7, CK19, or CD133. The histological features of scirrhous HCC are in line with its associations with activation of the transforming growth factor beta (TGF-β) pathway, overexpression of VIM, SNAIL, SMAD4, and TWIST, and characteristics of epithelial-to-mesenchymal transition. sixteen (16)

The hallmarks of steatohepatitic HCC (SH-HCC) include Mallory-Denk bodies, tumour cell ballooning, peri-cellular fibrosis, and intra-tumoral inflammatory infiltrates. Typically, these tumours are well-differentiated. (17) The phenotypic level shows that the neoplastic cells overexpress C-

reactive protein (CRP), a gene that is targeted by the Janus kinase/signal transducers and activators of transcription protein (JAK/STAT) signalling pathway. (16). Patients with non-alcoholic steato-hepatitis (NASH) and alcoholic steato-hepatitis (ASH) are more likely to have SH-HCC. Molecular similarities between SH-HCCs forming in ASH and NASH point to steato-hepatitis being a driver of cancer initiation rather than the underlying liver disease. (18). An good histological categorisation of HCC and surrounding hepatic backdrop is necessary to appropriately treat patients with various medications, since a recent research shown that immunotherapy is less effective against non-viral HCC, especially HCC that develops in the context of NASH (19)

On microscopic analysis, lymphocytes dominate the neoplastic cells in the majority of areas in lymphocyte-rich HCC, an uncommon histotype. There is evidence that intra-tumoral lymphocytic infiltration may have an anticancer impact, as HCCs rich in lymphocytes have been linked to better overall survival. Cytotoxic CD8+ T-lymphocytes with elevated PD-L1 and PD1 expression make up the vast majority of the infiltrating lymphocytes. These lymphocyte-rich HCCs did not show signs of microsatellite instability or an increased number of somatic mutations, in contrast to other cancers like lung and colon that have lymphocytic infiltration and been associated with high mutational burdens (20).

Making an HCC diagnosis

Discovering HCC before it progresses to later stages of illness may be tricky since it often develops and expands silently. A significant number of cancer fatalities are caused by hepatocellular carcinoma (HCC), but asymptomatic HCC is now more often found due to systematic monitoring of high-risk individuals. Aggressive treatments that have been shown to extend life are more likely to be appropriate for these patients whose tumours are detected before hepatic decompensation or other problems arise. (21).

Using imaging modalities is common practice when trying to make the challenging diagnosis of HCC. The objective is to identify tumours at a size of 2 cm or less so that all possible treatments may be considered. When patients have their tumours diagnosed early and treated, the five-year survival rate is higher than 70%. (21)

The onset of clinical deterioration, at which point survival is assessed in months, is often seen following a diagnosis of HCC. Screening and early detection of HCC can be achieved through surveillance of high-risk individuals for the disease. This is often done using multiple modalities to improve the accuracy of the screening and identify small tumours, which are often found in asymptomatic individuals and may be more responsive to invasive treatment options. Therefore, accurate diagnosis of HCC can reduce deaths and improve outcomes through treatment.

Treatment for HCC

Recently, there has been a significant improvement in the care of HCC, a neoplasia that is both common and deadly. Improved prognosis prediction and treatment sensitivity have resulted from advances in tumour natural history research and staging systems that categorise patients based on tumour features, liver disease, and performance status (e.g., the Barcelona Clinic Liver Cancer system). Curative therapy such as resection, transplantation, and ablation may enhance survival rates and provide hope for a permanent cure for individuals diagnosed with early-stage HCC. Sorafenib, a multi-kinase inhibitor with antiangiogenic and anti-proliferative properties, is helpful for patients diagnosed with advanced HCC, whereas chemoembolization is effective for those with intermediate stage (22).

The treatment of HCC may be approached in several ways, including the following:

Techniques that do not involve surgery include radiofrequency ablation, microwave ablation, percutaneous ethanol injection, trans-arterial chemoembolization (TACE), and medical procedures include hormonal and cytotoxic medication administration and tumour removal.

TACE

A large number of patients aren't eligible for curative surgical or non-surgical treatment due to advanced tumour stage or poor general patient condition; thus, there is a need for effective palliative and, to a lesser degree, curative treatment for HCC, despite the availability of numerous curative options. The survival advantage of (TACE) has only been shown, and it has already become a regular therapy for certain patients (24).

Types:

Two methods exist for transdermal acupuncture catheterisation: drug-eluting bead-assisted TACE (DEB-TACE) and conventional TACE (cTACE). Lipiodol is an oily radio-opaque substance that serves as both a chemotherapeutic carrier and an embolic material in cTACE. The procedure begins with the administration of a cytotoxic drug such doxorubicin, epirubicin, mitomycin, or cisplatin. Collage, degradable starch microspheres (DSM), and gelatine sponge are

among the other embolic agents that are often used. DEB-TACE is able to deliver chemotherapeutic medications in a sustained release form because it utilises non-resorbable embolic microspheres (25).

The following are the TACE criteria for the treatment of HCC:

Patients meeting the following criteria are eligible to participate: hepatocellular carcinoma (HCC) with one or more nodules, numerous bilobar metastases, a tumour size more than 3 cm that cannot be treated with ablation, and the absence of vascular invasion or extrahepatic dissemination in the patient (26).

Patients with peripheral vascular diseases, intolerance or allergy to contrast agents, poor liver function tests, portal vein thrombosis, arterio-portal shunts, severe disability or terminal illness, hemorrhagic diathesis (INR more than 1.4), extrahepatic metastasis, uncontrollable ascites, active esophageal varices, and other general contraindications to angiography are all excluded (26).

To get ready for TACE, patients must:

Patients with a confirmed diagnosis of HCC, either single or multiple, are screened for the procedure through pre-procedural imaging using US, abdominal CT, or MRI. Prior investigations such as virology, hepatic function tests, renal function tests, CBC, PT, PTT, and INR are also considered. A thorough patient history, including medical, surgical, and personal details, is taken, and the procedure is explained in detail before consent is obtained. Patients with known allergies to contrast media are not considered (27).

Procedure

After administering local anaesthesia, the following steps are taken: the femoral artery is perforated using a single-needle Seldinger technique; a 6-F angio-sheath is pushed into place; a cobra catheter is placed in the descending aorta using a Terumo guide wire; contrast agent is used to take cholec and hepatic angiograms; a micro-catheter can be used for more localisation of the feeding arteries if available; finally, chemotherapy agents (doxorubicin, cisplatin, or a combination of the two) are injected to close the feeding arteries (28).

Assessment Method for Children: The Child Pugh Scale

For the purpose of predicting mortality in cirrhosis patients, the Child-Pugh scoring system was developed. This method is also known as the Child-Pugh-Turcotte score. In 1964, Child and Turcotte developed a system to classify patients into three groups: A, who had good hepatic function, B, who had moderately impaired hepatic function, and C, who had advanced hepatic dysfunction. This system was used to select patients who would benefit from elective surgery for portal decompression. A patient's clinical nutrition status, ascites, serum bilirubin and albumin levels, neurological disease, and ascites were the five clinical and laboratory criteria that initially comprised their grading system. Subsequently, Pugh et al. adjusted the scoring method by replacing clinical nutrition status with prothrombin time (29).

Child-Pugh score

Parameter	1 point	2 points	3 points
ascites	none	slight	moderate to severe
encephalopathy	none	slight to moderate	moderate to severe
total bilirubin (mg/dL)	<2	2-3	>3
albumin (g/dL)	>3,5	2,8-3,5	<2,8
protrombin time (s)	1-3	4-6	>6

Class	Points
Child-Pugh A	5-6
Child-Pugh B	7-9
Child-Pugh C	10-15

Fig. (1) Using the Child-Pugh scale *(30)*

5. Conclusion

With a 60% complete response rate, the trial proved that TACE is a very successful treatment for early-stage hepatocellular carcinoma patients with Child-Pugh Grade A who are unable to undergo surgery. Importantly, the research found that a good prognosis after TACE is strongly predicted by a lower tumour size, the lack of an expanded belly, and ultrasonography homogeneity. In order to optimise patient selection and improve clinical results for HCC patients, it is crucial to consider tumour features and clinical presentation when predicting TACE outcomes.

References

[1] Parkin, D. M., Bray, F., Ferlay, J. & Pisani, P. 2001. Estimating the world cancer burden: Globocan 2000. *Int J Cancer,* 94, 153-6**.**

[2] Llovet, J. M., Fuster, J. & Bruix, J. 2004. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. *Liver Transpl,* 10, S115-20**.**

[3] Llovet, J. M., Real, M **.**I., Montaña, X., Planas, R., Coll, S., Aponte, J., et al. 2002. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. *Lancet,* 359, 1734-9**.**

[4] Raoul, J. L., Forner, A., Bolondi, L., Cheung, T. T., Kloeckner, R. & de Baere, T. 2019. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. *Cancer Treat Rev,* 72, 28-36**.**

[5] Takayasu, K., Arii, S., Ikai, I., Omata, M., Okita, K., Ichida, T., et al. 2006. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. *Gastroenterology,* 131, 461-9**.**

[6] Harkins, J. M. & Ahmad, B. 2023. Anatomy, abdomen and pelvis, portal venous system (hepatic portal system). *StatPearls [Internet]*. StatPearls Publishing**.**

[7] Frank, N. H. 2014. *Atlas of human anatomy / Frank H. Netter, MD,* Philadelphia **,**PA, Saunders/Elsevier**.**

[8] Luersen, G. F **,.**Bhosale, P. & Szklaruk, J. 2015. State-of-the-art cross-sectional liver imaging: beyond lesion detection and characterization. *J Hepatocell Carcinoma,* 2, 101-17**.**

[9] Stephanie, McNicholas, M., Ryan & Eustace, S. J. 2011. *Anatomy for Diagnostic Imaging E-Book: Anatomy for Diagnostic Imaging E-Book,* Elsevier Health Sciences**.**

[10] Ferlay, J., Soerjomataram, I., Dikshit **,** R., Eser, S., Mathers, C., Rebelo, M., et al. 2015. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer,* 136, E359-86**.**

[11] Jang, J. Y., Lee, J. S., Kim, H.-J., Shim, J.-J **,.**Kim, J. H., Kim, B. H., et al. 2017. The general rules for the study of primary liver cancer. *J Liver Cancer,* 17, 19-44**.**

[12] Lee, Y., Park, H., Lee, H., Cho, J. Y., Yoon, Y. S., Choi, Y. R., et al. 2018. The Clinicopathological and Prognostic Significance of the Gross Classification of Hepatocellular Carcinoma. *J Pathol Transl Med,* 52, 85-92**.**

[13] Yazdanpanah, S., Geramizadeh, B., Nikeghbalian, S. & Malek-Hosseini, S. A. 2016. Hepatocellular Carcinoma and Its Precursors in 103 HBV-Related Cirrhotic Explanted Livers: A Study from South Iran. *Hepat Mon,* 16, e38584**.**

[14] Vij, M. & Calderaro, J. 2021. Pathologic and molecular features of hepatocellular carcinoma: An update. *World J Hepatol,* 13, 393-410**.**

[15] Inchingolo, R., Faletti, R., Grazioli, L., Tricarico, E., Gatti, M., Pecorelli, A., et al. 2018. MR with Gd-EOB-DTPA in assessment of liver nodules in cirrhotic patients. *World J Hepatol,* 10, 462-473**.**

[16] Calderaro, J., Ziol, M., Paradis, V. & Zucman-Rossi, J. 2019. Molecular and histological correlations in liver cancer. *J Hepatol,* 71, 616-630**.**

[17] Salomao, M., Yu, W. M., Brown, R. S., Jr., Emond, J. C. & Lefkowitch, J. H. 2010. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. *Am J Surg Pathol* **,** ٣٤**,** ١٦٣٠-٦**.**

[18] Qin, J., Higashi, T., Nakagawa, S., Fujiwara, N., Yamashita, Y. I., Beppu, T., et al. 2020. Steatohepatitic Variant of Hepatocellular Carcinoma Is Associated With Both Alcoholic Steatohepatitis and Nonalcoholic Steatohepatitis: A Study of 2 Cohorts With Molecular Insights. *Am J Surg Pathol,* 44, 1406-1412**.**

[19] Pfister, D., Núñez, N. G **,.**Pinyol, R., Govaere, O., Pinter, M., Szydlowska, M., et al. 2021. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. *Nature,* 592, 450-456**.**

[20] Chan, A. W., Tong **,**J. H., Pan, Y., Chan, S. L., Wong, G. L., Wong, V. W., et al. 2015. Lymphoepithelioma-like hepatocellular carcinoma: an uncommon variant of hepatocellular

carcinoma with favorable outcome. *Am J Surg Pathol,* 39, 304-12**.**

[21] Marrero, J. A., Kulik, L. M., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., et al. 2018. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology,* 68, 723-750**.**

[22] Rashed, W. M., Kandeil, M. A. M., Mahmoud, M. O. & Ezzat, S. 2020. Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overview. *Journal of the Egyptian National Cancer Institute,* 32, 5**.**

[23] Revel-Mouroz, P., Otal, P., Jaffro, M., Petermann, A., Meyrignac, O., Rabinel, P., et al. 2017. Other non-surgical treatments for liver cancer. *Reports of Practical Oncology & Radiotherapy,* 22, 181-192**.**

[24] Kumar, A., Abbas, A. K. & Jon, C. 2018. Aster. Robbins basic pathology**.** Philadelphia: Elsevier**.**

[25] Raoul, J. L., Forner, A., Bolondi, L., Cheung, T. T., Kloeckner, R. & de Baere, T. 2019. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. *Cancer Treat Rev,* 72, 28-36**.**

[26] Sparchez, Z., Radu, P **,.**Bartos, A., Nenu, I., Craciun, R., Mocan, T., et al. 2021. Combined treatments in hepatocellular carcinoma: Time to put them in the guidelines? *World J Gastrointest Oncol,* 13, 1896-1918**.**

[27] Karim, M. A., Singal, A. G., Kum, H. C., Lee, Y. T., Park **,**S., Rich, N. E., et al. 2023. Prediagnostic CT or MRI Utilization and Outcomes in Hepatocellular Carcinoma: SEER-Medicare Database Analysis. *Cancer Res Commun,* 3, 874-883**.**

[28] Reddy, V., Todnem, N., Franco-Mesa, C., Erben, Y., Tawk, R. G. & Ritchie, C. 2021. Endovascular repair of a common femoral artery puncture after losing access using a vascular closure device. *J Vasc Surg Cases Innov Tech,* 7, 466-468**.**

[29] Child, C. G. & Turcotte, J. G. 1964. Surgery and portal hypertension. *Major Probl Clin Surg,* 1, 1-85**.**

[30] Chernyak, V., Fowler, K. J., Kamaya **,** A., Kielar, A. Z., Elsayes, K. M., Bashir, M. R., et al. 2018. Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. *Radiology,* 289, 816-830**.**